Human tumor necrosis factor
Patent 4677064 Issued on June 30, 1987. Estimated Expiration Date: 
May 2, 2005. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 2, 2005. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesProcesses for inserting DNA into eucaryotic cells and for producing proteinaceous materials Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same Process for producing target cell lysis factor and uses therewith Patent #: 4495282 InventorsAssigneeApplicationNo. 06/730696 filed on 05/02/1985US Classes:435/69.1, Recombinant DNA technique included in method of making a protein or polypeptide424/85.1, LYMPHOKINE435/252.3, Transformants (e.g., recombinant DNA or vector or foreign or exogenous gene containing, fused bacteria, etc.)435/320.1, VECTOR, PER SE (E.G., PLASMID, HYBRID PLASMID, COSMID, VIRAL VECTOR, BACTERIOPHAGE VECTOR, ETC.) BACTERIOPHAGE VECTOR, ETC.)514/8, Glycoprotein (carbohydrate containing)530/350, PROTEINS, I.E., MORE THAN 100 AMINO ACID RESIDUES530/351, Lymphokines, e.g., interferons, interlukins, etc.530/395, Glycoprotein, e.g., mucins proteoglycans, etc.530/808, MATERIALS AND PRODUCTS RELATED TO GENETIC ENGINEERING OR HYBRID OR FUSED CELL TECHNOLOGY, E.G., HYBRIDOMA, MONOCLONAL PRODUCTS, ETC.536/23.1, DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)536/23.5, Encodes an animal polypeptide536/24.1, Non-coding sequences which control transcription or translation processes (e.g., promoters, operators, enhancers, ribosome binding sites, etc.)930/144Tumor necrosis factorExaminersPrimary: Wiseman, Thomas G.Assistant: Teskin, Robin L. Attorney, Agent or FirmInternational ClassesC07K 14/525 (20060101)C07K 14/435 (20060101) A61K 38/00 (20060101) AbstractHuman Tumor necrosis factor (TNF) has been prepared using recombinant methods. A human promyelocytic leukemia cell line has been induced using an improved induction procedure, and the TNF purified to homogeneity. Methods, vectors, and cells useful in obtaining human TNF in practical amounts are disclosed. Muteins having N-terminal deletions, which muteins have superior biological activity, are also disclosed.Other References
|
| ||||||||||||||
